Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Dare Bioscience's Debt-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DARE vs OTLC, PASG, SYBX: Debt-to-Asset Comparison
For the Biotechnology subindustry, Dare Bioscience's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dare Bioscience Debt-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dare Bioscience's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where Dare Bioscience's Debt-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience (DARE) has a Debt-to-Asset of 0.30 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Dare Bioscience and its competitors.
Is Dare Bioscience's Debt-to-Asset too high?
Dare Bioscience's current Debt-to-Asset is 0.30. Overall, Dare Bioscience has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's Debt-to-Asset compare to OTLC and PASG?
Dare Bioscience's Debt-to-Asset of 0.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Dare Bioscience and its competitors. Dare Bioscience's current Debt-to-Asset is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Dare Bioscience (DARE) is currently considered Possible Value Trap. The stock's GF Value™ is $2.38, compared to a current price of $0.88 — trading 63.1% below its estimated fair value. The current Debt-to-Asset is 0.30. Dare Bioscience's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Dare Bioscience (DARE), the current Debt-to-Asset is 0.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dare Bioscience (DARE) Overvalued in 2026?
Based on GuruFocus' analysis, Dare Bioscience stock appears to be undervalued.
The current stock price of $0.88 is trading 63.1% below its estimated GF Value™ of $2.38.
GuruFocus considers Dare Bioscience to be Possible Value Trap.
Key valuation signals for DARE:
Debt-to-Asset: 0.30
GF Value™: $2.38 vs. price of $0.88 (63.1% below fair value)
No single metric tells the full story. See the DARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dare Bioscience Inc. is a biopharmaceutical company focused on women's health, based in the United States. It identifies, develops, and commercializes differentiated therapies in contraception, fertility, and vaginal and sexual health. Its first commercial product, XACIATO (clindamycin phosphate vaginal gel, 2%), is a single-dose prescription treatment for bacterial vaginosis in females aged 12 and older. The company's development portfolio includes Ovaprene, an investigational hormone-free monthly contraceptive, and Sildenafil Cream, an investigational topical treatment for female sexual arousal disorder. Dare Bioscience operates as a single reporting segment, women's health, and generates revenue primarily through product sales of XACIATO and collaboration and licensing arrangements with partners. Its customers are healthcare providers, pharmacies, and patients in the United States, and it works with strategic partners to support development and commercialization.
28GF Score
Get the complete analysis for DARE
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DARE has been successfully added to your 
